Harrow, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow, Inc. on October 25, 2024. The filing details a material definitive agreement regarding the company's credit facilities and a significant milestone payment related to its commercial product, Triescence.
Key Financial Metrics and Transactions
- Milestone Payment: The Company made a one-time payment of $37,000,000 to Novartis Technology, LLC and Novartis Innovative Therapies AG on October 15, 2024, triggered by the commercial availability of Triescence.
- Debt Drawdown: On October 25, 2024, the Company drew down $30,000,000 under its pre-existing Oaktree Loan commitment to partially fund the Novartis payment.
- Total Debt Utilization: Following this draw, the total principal loan amount drawn under the Oaktree Loan is $107,500,000. No additional principal remains available under this facility.
- Registered Securities: Common Stock (HROW), 8.625% Senior Notes due 2026 (HROWL), and 11.875% Senior Notes due 2027 (HROWM) are registered on The Nasdaq Stock Market LLC.
Material Changes and Agreement Terms
The Company entered into a Second Amendment to its Credit Agreement and Guaranty with Oaktree Fund Administration, LLC. Key terms of this amendment include:
- Waiver of Make-Whole Costs: Oaktree agreed to waive make-whole costs associated with the $30,000,000 draw if the debt is repaid before March 31, 2025.
- Leverage Ratio Exclusion: The $30,000,000 draw is excluded from the calculation of the Total Leverage Ratio defined in the Oaktree Loan.
- No Other Changes: No other material changes to the Oaktree Loan were provided in the Second Amendment.
Outlook, Risks, and Management Commentary
The filing confirms the commercial availability of Triescence, a key milestone for the Company. The full text of the Second Amendment is expected to be filed as an exhibit to the Quarterly Report on Form 10-Q for the three months ended September 30, 2024. The filing does not provide specific forward-looking guidance, risk factors, or liquidity metrics beyond the debt utilization status.
Investor Verification Checklist
- Verify the impact of the $37,000,000 milestone payment on the Company's current cash position and liquidity.
- Confirm the total outstanding debt obligations, including the $107,500,000 Oaktree Loan and the two classes of Senior Notes.
- Review the upcoming Form 10-Q for the full text of the Second Amendment to the Credit Agreement.
- Assess the Company's ability to service its debt given that no additional principal is available under the Oaktree Loan.